Y-mAbs Therapeutics, Inc.
YMAB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for YMAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Tracking 3 clinical trials for Y-mAbs Therapeutics, Inc..
Run Y-mAbs Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Y-mAbs Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.34
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Regulatory
Financials
Governance
Frequently asked questions
Who is the CEO of Y-mAbs Therapeutics, Inc.?
Michael Rossi is the chief executive officer of Y-mAbs Therapeutics, Inc. (YMAB).
What therapeutic areas does Y-mAbs Therapeutics, Inc. focus on?
Y-mAbs Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.